Theriva Biologics Q2 net loss narrows 75.37% to $3.22 million
TOVX•VIRAGE2 trial advances
First patients were dosed in the VIRAGE2 Phase 2a trial of VCN-01 in metastatic PDAC; enrollment is expected in H2 2026 with initial safety data due Q3 2027.
Cash balance and runway
Cash and cash equivalents totaled $11.34 million at June 30, 2026; management said the cash runway extends into Q1 2027.
Q2 loss narrows as expenses decline
Theriva Biologics posted a Q2 2026 net loss attributable to common stockholders of $3.22 million, narrowing from $13.06 million a year earlier.
Operating loss narrowed to $3.3 million from $13.13 million, as general and administrative expense fell 82% to $2.03 million.
Research and development spending falls
Research and development expense dropped to , reflecting lower clinical trial costs, partly offset by higher manufacturing activity.
